Enhanced EPR effects by tumour stromal cell mimicking nanoplatform on invasive pituitary adenoma

Rapid advances in nanomedicine have enabled potential applications in cancer therapy. The enhanced permeability and retention (EPR) effect is the primary rationale for the passive targeting of nanoparticles in oncology. However, growing evidence indicates that the accumulation of nanomaterials via t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Materials today bio 2024-02, Vol.24, p.100895-100895, Article 100895
Hauptverfasser: Ma, Junning, Yin, Wei, Zhang, Xiaojian, Lin, Lu, Bao, Youmei, Dai, Lisi, Cao, Hui, Chen, Honghwei, Yu, Jianbo, Yang, Jiqi, Zhang, Yue, Lan, Huimin, Li, XueYang, Huang, Qiong, Yang, Dan, Yu, Yajun, Chen, Jingyao, Zhang, Chengchen, Liu, Li, Lei, Chen, Zhan, Renya, Liu, Fei
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Rapid advances in nanomedicine have enabled potential applications in cancer therapy. The enhanced permeability and retention (EPR) effect is the primary rationale for the passive targeting of nanoparticles in oncology. However, growing evidence indicates that the accumulation of nanomaterials via the EPR effect could be more efficient. Inspired by our clinical observation of the Gap Junction connecpion between folliculostellate cells and pituitary adenoma cells, we designed a novel drug delivery system that targets tumours by coating folliculostellate cell (FS) membranes onto PLGA nanoparticles (NPs). The resulting FSNPs, inheriting membrane proteins from the folliculostellate cell membrane, significantly enhanced the EPR effect compared to nanoparticles without cancer cell membranes. We further demonstrated that mitotane encapsulation improved the therapeutic efficacy of mitotane in both heterotopic and orthotopic pituitary adenoma models. Owing to its significant efficacy, our FS cell membrane-coated nanoplatforms has the potential to be translated into clinical applications for the treatment of invasive pituitary adenoma. [Display omitted]
ISSN:2590-0064
2590-0064
DOI:10.1016/j.mtbio.2023.100895